SNStefan Neuburger

Stefan Neuburger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefan Neuburger has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • B. Doerken

    Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany

    1 shared publication
  • B. Graf

    Institute of Microbiology, Charité University Medicine Berlin, Berlin, Germany

    1 shared publication
  • C. Lutz

    Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany

    1 shared publication
  • G. Massenkeil

    Department of Internal Medicine, Hematology and Oncology, Ruhr‐University Bochum, Bochum, Germany

    1 shared publication
  • Georg Maschmeyer

    German Society of Hematology and Medical Oncology (DGHO) and Charité University Medicine Berlin, Campus Benjamin Franklin; Department of Hematology, Oncology and Tumor, Charité University Medicine Berlin, Berlin, Germany

    1 shared publication
  • I. Tamm

    Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany

    1 shared publication

Latest Publications

  • Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation

    by S. Neuburger, G. Massenkeil, M. Seibold, C. Lutz, I. Tamm, P. Le Coutre, B. Graf, B. Doerken, R. Arnold

    Fusarium infections are associated with high mortality after allogeneic stem cell transplantation. We report on successful treatment of a disseminated cutaneous Fusarium proliferatum infection using liposomal amphotericin B and terbinafine. In vitro susceptibility tests of antifungal drugs suggest that terbinafine is a potent additional antifungal drug for disseminated cutaneous fusariosis.


  • Update on management of infections in cancer and stem cell transplant patients

    by Stefan Neuburger, Georg Maschmeyer

    Infections are the most important causes of morbidity and mortality in patients with aggressive malignancies and those undergoing allogeneic stem cell transplantation. The introduction of new therapeutic approaches including the use of nucleoside analogs and of monoclonal antibodies to CD20 and CD52 and the increased use of matched unrelated stem cell donors has resulted in new challenges with regard to systemic viral and fungal infections. In patients with bacterial infections, emergence of resistance to formerly widely used antibiotics as well as a shift of causative pathogens towards a predominance of multi-resistant gram-positive cocci has to be taken into consideration. In high-risk neutropenic patients with fever of unknown origin, prompt empiric monotherapy with piperacillin–tazobactam, cefepime, ceftazidime, or a carbapenem is mandatory. In patients with lung infiltrates, early preemptive intervention with an antifungal active against aspergilli is recommended, whereas in patients with catheter-related, skin or soft tissue infections, preemptive addition of a glycopeptide shows a high response rate. The prompt preemptive use of ganciclovir or foscarnet in allogeneic stem cell transplant recipients can reliably be guided by serial monitoring of cytomegalovirus antigen and polymerase chain reaction monitoring.